Related Experiment Video
Updated: Oct 18, 2025
Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
Published on: March 30, 2022
Production of a Soluble Recombinant Antibody Fragment against MMP9 Using Escherichia coli
Chang-Hun Yeom1, Hee-Jin Jeong1
1Department of Biological and Chemical Engineering, Hongik University, Sejong 30016, Korea.
Abstract:
Matrix metalloproteinase 9 (MMP9) is involved in several aspects of the pathology of cancer, including invasion, metastasis, and angiogenesis. In this study, we expressed a recombinant scFv-type anti-MMP9 antibody in soluble form using Escherichia coli, purified it, and confirmed its antigen-binding ability. The convenient, rapid, inexpressive system used in this study for producing recombinant antibody fragments needs only five days, and thus can be used for the efficient production of scFv against MMP9, which can be used in a range of applications and industrial fields, including diagnosis and treatment of inflammatory and cancer-related diseases.
Insights
Researchers developed a rapid method to produce a recombinant antibody fragment targeting matrix metalloproteinase 9 (MMP9). This efficient production system for anti-MMP9 scFv antibodies can aid in diagnosing and treating cancer and inflammatory diseases.
Area of Science:
- Biotechnology
- Molecular Biology
- Immunology
Background:
- Matrix metalloproteinase 9 (MMP9) plays a critical role in cancer progression, including invasion, metastasis, and angiogenesis.
- Targeting MMP9 is a potential therapeutic strategy for various cancers and inflammatory conditions.
Purpose of the Study:
- To develop an efficient system for producing recombinant single-chain variable fragment (scFv) antibodies against MMP9.
- To confirm the antigen-binding ability of the produced anti-MMP9 scFv.
Main Methods:
- Expression of a recombinant scFv-type anti-MMP9 antibody in soluble form using *Escherichia coli*.
- Purification of the recombinant antibody fragment.
- Confirmation of antigen-binding ability.
Main Results:
- A soluble recombinant scFv-type anti-MMP9 antibody was successfully expressed and purified.
- The purified antibody fragment demonstrated specific binding to its antigen, MMP9.
- The production system is rapid, requiring only five days.
Conclusions:
- An efficient and rapid method for producing anti-MMP9 scFv antibodies has been established using *Escherichia coli*.
- The recombinant anti-MMP9 scFv holds promise for applications in the diagnosis and treatment of cancer and inflammatory diseases.
- This technology facilitates the industrial production of valuable antibody fragments.
